MS-1 peptide is a peptide for BH3 profiling. MS-1 peptide triggers higher depolarization of mitochondrial membrane in melanoma cells pre-treated with Encorafenib. MS1 peptide can be used for the research of BRAF V600E melanoma [1].
In Vitro, MS1 peptide (4-8 μM) significantly increases mitochondrial membrane depolarization in encorafenib-pretreated DMBC11, DMBC12, DMBC21, DMBC28, and DMBC29 BRAFV600E melanoma cells, indicating altered cell dependence on anti-apoptotic proteins after encorafenib exposure[1].
References:
[1]. Hartman ML, et al. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF V600E melanoma cells. Cancer Lett. 2021;499:122-136.
In Vitro, MS1 peptide (4-8 μM) significantly increases mitochondrial membrane depolarization in encorafenib-pretreated DMBC11, DMBC12, DMBC21, DMBC28, and DMBC29 BRAFV600E melanoma cells, indicating altered cell dependence on anti-apoptotic proteins after encorafenib exposure[1].
References:
[1]. Hartman ML, et al. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF V600E melanoma cells. Cancer Lett. 2021;499:122-136.